摘要
目的观察缬沙坦治疗慢性心力衰竭的临床疗效。方法心力衰竭患者58例,随机分为两组:即缬沙坦治疗组30例服用缬沙坦80 mg/d;常规治疗组28例未服用缬沙坦及其他血管紧张素Ⅱ-1型受体拮抗剂。缬沙坦组和常规治疗组均于治疗前,治疗后半年分别行心脏彩色多普勒检查。结果两组在治疗前及治疗后对比,缬沙坦组比常规治疗组左心室舒张末期容积(LVEDV)[(102.6±25.6)mlvs.(117.2±28.5)ml,P<0.05]及左心室收缩末期容积(LVESV)[(53.1±20.6)mlvs.(66.4±28.7)ml,P<0.05]明显减小,而左室射血分数(LVEF)明显提高[(56.1±9.6)%vs.(47.4±13.2)%,P<0.01]。随访1年,结果缬沙坦组(24.0%)比常规治疗组(46.7%)心力衰竭再发生率降低有统计学意义(P<0.05)。结论应用缬沙坦治疗心力衰竭,患者心功能有明显的改善。
Objective To observe the effect of valsartan on chronic heart failure. Methods Fifty-eight chronic heart failure patients were randomly divided into two groups: 30 patients treated with Valsartan (Valsartan group) and 28 patients received stardard therapies plus without Valsartan or any other angiotensin Ⅱ type 1 receptor blockade (control group). Both groups underwent echocardiography before and 6 months after treatment. Results In Valsartan group, left ventricular end-diastolic volume (LVEDV) [ ( 102.6 ± 25.6 ) ml vs. ( 117.2 ± 28.5) ml, P〈 0.05]and left ventricular end-systolic volume(LVESV) [(53.1±20.6)ml vs. (66.4±28.7)ml, P〈0.05] were significantly decreased after treatment while left ventricular ejection fraction(LVEF) [(56. 1±9. 6)% us. ( 47.4±13. 2)%, P〈0.01] was significantly increased. After one year's follow up, the rate of recurrent heart failure in Valsartan group was significantly lower than in control group (24.0% vs. 46.7%, P〈0.05). Conclusions Valsartan can prevent ventriclular remolding and decrease recurrent heart failure.
出处
《中国心血管杂志》
2007年第6期445-447,共3页
Chinese Journal of Cardiovascular Medicine
关键词
缬沙坦
心力衰竭
Valsartan
Heart Failure